SCHEMBL1667775

SCHEMBL1667775

CCOC(=O)Oc1cc(F)c(C=O)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.42
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
CA2 P00918 1/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP14 P50281 1/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 1/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SOAT1 P35610 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665868 0.81 LMNA (0.38) CYP3A4SMN1; SMN2CA2ALDH1A1MMP2
SCHEMBL1667625 0.80 KMT2A (0.48) KMT2ASMN1; SMN2CA2ALDH1A1POLB
SCHEMBL27169475 0.78 GAA (0.50) KMT2ACYP3A4SMN1; SMN2ALDH1A1POLB
SCHEMBL1791270 0.78 CYP4F2 (0.46) KMT2ACA2ALDH1A1POLBMEN1
SCHEMBL1665879 0.77 MMP2 (0.36) SMN1; SMN2CA2MMP2MMP9MMP14
SCHEMBL15322471 0.77 CA12 (0.53) KMT2AUSP2CYP3A4SMN1; SMN2CA2
SCHEMBL18272440 0.77 KMT2A (0.50) KMT2ASMN1; SMN2CA2ALDH1A1POLB
SCHEMBL8007532 0.75 LMNA (0.42) SMN1; SMN2CA2ALDH1A1RAB9AMAPT
SCHEMBL28332668 0.74 MEN1 (0.44) KMT2AMEN1LMNA
SCHEMBL28972926 0.73 CA2 (0.37) KMT2ACA2MEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493905-B1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT CO LLC (PR) 2016-11-30 EP disclosed
US-8822435-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-09-02 US disclosed
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2014-07-10 US disclosed
US-8710215-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-04-29 US disclosed
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2013-02-07 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
EP-2493905-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS Warner Chilcott Company, LLC (PR) 2012-09-05 EP disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885USP2 4203/4885CYP3A4 2564/4885
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885USP2 4203/4885CYP3A4 2564/4885
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN KMT2A 4240/4885USP2 4203/4885CYP3A4 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.